Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

被引：0
|
作者：
Kalinsky, Kevin
Tolcher, Anthony W.
Wang, Shushen
Meric-Bernstam, Funda
Winkler, Robert
Li, Mingyu
Sun, Xuemei
Pan, Wentao
Paudyal, Bishnuhari
Liang, Zhiyan
Lu, Ming
Yang, Dajun
Zhai, Yifan
机构：
[1] Emory Univ, Winship Canc Inst, Glenn Family Breast Ctr, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Winship Canc Inst, Breast Med Oncol, Atlanta, GA USA
[3] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[4] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1122
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC)
    Wander, Seth A.
    Cohen, Ofir
    Gong, Xueqian
    Johnson, Gabriela N.
    Buendia-Buendia, Jorge
    Lloyd, Maxwell
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Helvie, Karla
    Kowalski, Kailey
    Nayar, Utthara
    Parsons, Stephen
    Martinez, Ricardo
    Litchfield, Lacey
    Ye, Xiang
    Yu, Chun Ping
    Jansen, Valerie
    Garraway, Levi A.
    Winer, Eric P.
    Tolaney, Sara M.
    Lin, Nancy U.
    Buchanan, Sean
    Wagle, Nikhil
    CANCER RESEARCH, 2020, 80 (04)
  • [22] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
    Patel, Manish R.
    Juric, Dejan
    Henick, Brian S.
    Moore, Kathleen N.
    Do, Doreen
    Chapman, Joshua
    Zhang, Hui
    Roche, Maria
    Newberry, Kate J.
    Rinne, Mikael
    Yap, Timothy A.
    CANCER RESEARCH, 2023, 83 (05)
  • [23] Alpelisib plus endocrine therapy (ET) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
    Juric, Dejan
    Turner, Nicholas
    Prat, Aleix
    Chia, Stephen
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Bachelot, Thomas
    Balbin, O. Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [24] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
    De Laurentiis, Michelino
    Costa, Luis
    Gligorov, Joseph
    Knop, Ann
    Senkus-Konefka, Elzbieta
    Garcia-Saenz, Jose A.
    Schmid, Peter
    Heniquez, Aurelia
    Serra, Paolo
    Reising, Albert
    Kuemmel, Sherko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
    Gao, Jennifer J.
    Cheng, Joyce
    Prowell, Tatiana M.
    Bloomquist, Erik
    Tang, Shenghui
    Wedam, Suparna B.
    Royce, Melanie
    Krol, Danielle
    Osgood, Christy
    Ison, Gwynn
    Sridhara, Rajeshwari
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    LANCET ONCOLOGY, 2021, 22 (11): : 1573 - 1581
  • [26] RESULTS OF A RANDOMIZED PHASE 2 STUDY OF PD 0332991, A CYCLIN-DEPENDENT KINASE (CDK) 4/6 INHIBITOR, IN COMBINATION WITH LETROZOLE VS LETROZOLE ALONE FOR FIRST-LINE TREATMENT OF ER +/HER2-ADVANCED BREAST CANCER (BC)
    Finn, R. S.
    Crown, J. P.
    Boer, K.
    Lang, I.
    Parikh, R. J.
    Breazna, A.
    Ho, S. N.
    Kim, S. T.
    Randolph, S.
    Slamon, D. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 43 - 43
  • [27] PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
    Mayer, Erica L.
    Ren, Yue
    Wagle, Nikhil
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy D.
    Abdou, Yara
    Riley, Elizabeth C.
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Sinclair, Natalie
    Faggen, Meredith
    Block, Caroline C.
    Ko, Naomi
    Partridge, Ann H.
    Chen, Wendy Y.
    Demeo, Michelle
    Attaya, Victoria
    Okpoebo, Amanda
    Alberti, Jillian
    Liu, Yuan
    Gauthier, Eric
    Burstein, Harold J.
    Regan, Meredith M.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17) : 2050 - 2060
  • [28] The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Man Cheung, Ka
    Chan, Jeffrey C. H.
    JAMA NETWORK OPEN, 2021, 4 (11)
  • [29] Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
    Battisti, Nicolo Matteo Luca
    De Glas, Nienke
    Sedrak, Mina S.
    Loh, Kah Poh
    Liposits, Gabor
    Soto-Perez-de-Celis, Enrique
    Krok-Schoen, Jessica L.
    Menjak, Ines B.
    Ring, Alistair
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [30] Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC)
    Finn, R. S.
    Crown, J. P.
    Lang, I.
    Boer, K.
    Bondarenko, I. M.
    Kulyk, S. O.
    Ettl, J.
    Patel, R.
    Pinter, T.
    Schmidt, M.
    Shparyk, Y.
    Thummala, A. R.
    Voytko, N. L.
    Breazna, A.
    Kim, S. T.
    Randolph, S.
    Slamon, D. J.
    CANCER RESEARCH, 2012, 72
12345